Stelara 130 MG/26 ML vial 26ML
Ended Awarded
- Contract number
- SPE2DR26FMDW8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,307
Award facts
- Contract value 100% obligated
- $10,307.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,307.36 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 130 mg/26 ml vials. The award, issued on November 14, 2025, carries an ultimate completion date of December 8, 2025, and involves no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's newly awarded Indefinite Delivery Contract (IDC) under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which carries a $499,999,999 ceiling value and extends through December 31, 2036.
The PPV-G GEN V represents part of the broader $30.3 billion Defense Logistics Agency pharmaceutical supply strategy designed to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's IDC authorizes the delivery of an extensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, vaccines, and medical consumables. The company's substantial federal contracting activity and demonstrated performance across multiple therapeutic categories, including oncology treatments, immunosuppressants, specialty pharmaceuticals, and routine medications, positions it as a critical supplier within the military medical supply chain. This particular delivery order for Stelara, a biologic immunosuppressant, reflects the company's established capability to fulfill specialized pharmaceutical requirements essential to DoD healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FMDW8?
SPE2DR26FMDW8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FMDW8 worth?
The government has obligated $10,307 on SPE2DR26FMDW8.
Is contract SPE2DR26FMDW8 an order under another contract?
Yes. SPE2DR26FMDW8 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDW8 competed?
The extent of competition for SPE2DR26FMDW8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award